Safety of middle meningeal artery embolization for treatment of subdural hematoma: A nationwide propensity score matched analysis
10.7461/jcen.2023.E2023.05.003
- Author:
Carson P. MCCANN
1
;
Michael G. BRANDEL
;
Arvin R. WALI
;
Jeffrey A. STEINBERG
;
J. Scott PANNELL
;
David R. SANTIAGO-DIEPPA
;
Alexander A. KHALESSI
Author Information
1. Department of Neurosurgery, University of California, San Diego, CA, USA
- Publication Type:Clinical Article
- From:Journal of Cerebrovascular and Endovascular Neurosurgery
2023;25(4):380-389
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:Middle meningeal artery embolization (MMAe) has burgeoned as a treatment for chronic subdural hematoma (cSDH). This study evaluates the safety and short-term outcomes of MMAe patients relative to traditional treatment approaches.
Methods:In this retrospective large database study, adult patients in the National Inpatient Sample from 2012-2019 with a diagnosis of cSDH were identified. Cost of admission, length of stay (LOS), discharge disposition, and complications were analyzed. Propensity score matching (PSM) was utilized.
Results:A total of 123,350 patients with cSDH were identified: 63,450 without intervention, 59,435 surgery only, 295 MMAe only, and 170 surgery plus MMAe. On PSM analysis, MMAe did not increase the risk of inpatient complications or prolong the length of stay compared to conservative management (p>0.05); MMAe had higher cost ($31,170 vs. $10,768, p<0.001) than conservative management, and a lower rate of nonroutine discharge (53.8% vs. 64.3%, p=0.024). Compared to surgery, MMAe had shorter LOS (5 vs. 7 days, p<0.001), and lower rates of neurological complications (2.7% vs. 7.1%, p=0.029) and nonroutine discharge (53.8% vs. 71.7%, p<0.001). There was no significant difference in cost (p>0.05).
Conclusions:MMAe had similar LOS and decreased odds of adverse discharge with a modest cost increase compared to conservative management. There was no difference in inpatient complications. Compared to surgery, MMAe treatment was associated with decreased LOS and rates of neurological complications and nonroutine discharge. This nationwide analysis supports the safety of MMAe to treat cSDH.
